Generic Myhibbin Availability
Last updated on Apr 10, 2025.
Myhibbin is a brand name of mycophenolate mofetil, approved by the FDA in the following formulation(s):
MYHIBBIN (mycophenolate mofetil - suspension;oral)
-
Manufacturer: AZURITY
Approval date: May 1, 2024
Strength(s): 200MG/ML [RLD]
Is there a generic version of Myhibbin available?
No. There is currently no therapeutically equivalent version of Myhibbin available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Myhibbin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical suspension for oral dosage
Patent 11,931,455
Issued: March 19, 2024
Inventor(s): Mehta; Sandip et al.
Assignee(s): LIQMEDS WORLDWIDE LIMITED (Hayes, GB)Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
Patent expiration dates:
- August 16, 2039✓✓
- August 16, 2039
-
Mycophenolate oral suspension
Patent 12,097,284
Issued: September 24, 2024
Inventor(s): Mehta; Sandip et al.
Assignee(s): LIQMEDS WORLDWIDE LIMITED (Hayes, GB)Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
Patent expiration dates:
- August 16, 2039✓
- August 16, 2039
-
Mycophenolate oral suspension
Patent 12,097,285
Issued: September 24, 2024
Inventor(s): Mehta; Sandip et al.
Assignee(s): LIQMEDS WORLDWIDE LIMITED (Hayes, GB)Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
Patent expiration dates:
- August 16, 2039✓✓
- August 16, 2039
-
Mycophenolate oral suspension
Patent 12,194,143
Issued: January 14, 2025
Inventor(s): Mehta; Sandip et al.
Assignee(s): LIQMEDS WORLDWIDE LIMITED (Hayes, GB)Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water, a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
Patent expiration dates:
- August 16, 2039✓✓
- August 16, 2039
-
Mycophenolate oral suspension
Patent 12,226,526
Issued: February 18, 2025
Inventor(s): Mehta; Sandip et al.
Assignee(s): LIQMEDS WORLDWIDE LIMITED (Hayes, GB)Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
Patent expiration dates:
- August 16, 2039✓✓
- August 16, 2039
More about Myhibbin (mycophenolate mofetil)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
